Use of Insulin Glargine During Pregnancy in Seven Type 1 Diabetic Women
- Jorien M. Woolderink, MD1,
- Aren J. van Loon, MD, PHD1,
- Fred Storms, MD2,
- Loek de Heide, MD3 and
- Klaas Hoogenberg, MD, PHD4
- 1Department of Obstetrics and Gynecology, Martini Ziekenhuis, Groningen, the Netherlands
- 2Department of Internal Medicine, Mesos Medisch Centrum, Bilthoven, the Netherlands
- 3Department of Internal Medicine, Medisch Centrum, Leeuwarden, the Netherlands
- 4Department of Internal Medicine, Martini Ziekenhuis, Groningen, the Netherlands.
- Address correspondence to K. Hoogenberg, MD, PhD, Martini Hospital, Department of Internal Medicine, PO Box 30033, 9700 RM Groningen, Netherlands. E-mail: k.hoogenberg{at}mzh.nl
Insulin glargine is a human insulin analog with an activity that results in a relatively constant concentration/time profile over 24 h with no pronounced peak. It is increasingly recognized to provide good glycemic control and to reduce the risk of hypoglycemia in type 1 diabetes (1). There may be a place for insulin glargine in diabetic pregnancies in which strict glycemic control and prevention of hypoglycemia reduce the higher adverse outcome risk. Despite animal studies showing the safety and efficacy of insulin glargine during pregnancy (2), its use in human pregnancies is currently not recommended. There are two case reports on the occasional use of insulin glargine during pregnancy (3, 4) and a notification of its safety in five patients during the first weeks of pregnancy (5). To …
